Evofem - About the company
Evofem is an acquired company based in San Diego (United States), founded in 2009. It operates as a Developer of therapeutics for reproductive care for women. Evofem has raised $100M in funding. The company has 114 active competitors, including 32 funded and 22 that have exited. Its top competitors include companies like BioNTech, Insmed and Aridis Pharma.
Company Details
Developer of therapeutics for reproductive care for women. It offers a lead product Phexxi vaginal gel that provides women with an in-the-moment contraceptive that maintains the baseline vaginal pH environment. It also offers a drug candidate EVO200 a vaginal pH modulator for the prevention of recurrent Bacterial Vaginosis.
- Website
- Social
- Registered Address
- 12400 High Bluff Dr. Suite 600 San Diego, CA 92130
Key Metrics
Founded Year
2009
Location
San Diego, United States
Stage
Acquired
Total Funding
in 14 rounds
Latest Funding Round
Investors
Ranked
6th among
Annual Revenue
as on Dec 31, 2023
Employee Count
as on Feb 28, 2022
Similar Companies
BioNTech &
Exit Details
Acquired by Aditx Therapeutics (Dec 12, 2023)
Legal entities associated with Evofem
Evofem is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CIN: 20-8527075 United States, Active | Jan 31, 2007 | $18.2M (as on Dec 31, 2023) | 119 (as on Feb 28, 2022) | - |
Get your free copy of Evofem's company profile
Evofem's acquisition details
Evofem got acquired by Aditx Therapeutics on Dec 12, 2023.
Click to take a look at Evofem's acquisition in detail
Evofem's funding and investors
Evofem has raised a total funding of $100M over 14 rounds. Its first funding round was on Dec 08, 2009.
Evofem has 4 institutional investors including PDL Biopharma, Woodford Investment Management and Adjuvant Capital.
Here is the list of recent funding rounds of Evofem:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Apr 08, 2025 | $750K | Post IPO | 3205818 | 2314168 | - |
Sep 27, 2023 | $2.88M | Post IPO | 6710988 | 6646573 | - |
Mar 02, 2023 | $1.38M | Post IPO | 5008750 | 7937235 | - |
Access funding benchmarks and valuations. Sign up today!View details of Evofem's funding rounds and investors
Evofem's founders and board of directors
Evofem's employee count trend
Evofem has 119 employees as of Feb 22. The total employee count is 19.0% lower than what it was in Feb 21. Here is Evofem's employee count trend over the years:
Uncover Evofem's growth story! Sign up today!
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Evofem's Competitors and alternates
Top competitors of Evofem include BioNTech, Insmed and Aridis Pharma. Here is the list of Top 10 competitors of Evofem, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st | Developer of immunotherapeutics for the treatment of cancer and other diseases | $806M | 67/100 | ||
2nd | Insmed 1999, Bridgewater (United States), Public | Developer of small molecule inhibitors for rare lung diseases | - | 62/100 | |
3rd | Aridis Pharma 2005, San Jose (United States), Public | Provider of human monoclonal antibodies against infectious diseases | $42.1M | , 听&补尘辫;听 | 59/100 |
4th |  Eligo Bioscience 2014, Paris (France), Series B | Developer of microbiome gene therapies against infectious disease | $52.3M | Seventure Partners, Sanofi Ventures听&补尘辫;听 | 55/100 |
5th | MaaT Pharma 2014, Lyon (France), Public | Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases | $42.3M | 55/100 | |
6th | 2009, San Diego (United States), Acquired | Developer of therapeutics for reproductive care for women | $100M | 54/100 | |
7th | ILiAD Biotechnologies 2012, New York City (United States), Series D | Developer of immunity-inducing vaccine for the prevention and treatment of pertussis | $51.2M | 54/100 | |
8th | Basilea 1999, Basel (Switzerland), Public | Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases | - | 52/100 | |
9th |  Lodo Therapeutics 2015, New York City (United States), Acquired | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | $19.9M | 52/100 | |
10th | Prokarium 2012, Keele (United Kingdom), Series C | Oral vaccines by re-engineering Salmonella into an efficient vaccine platform for a variety of infectious diseases. | $61.6M | 51/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Evofem's competitors? Click to see the top ones
Evofem's Investments and acquisitions
Evofem has made no investments or acquisitions yet.
Reports related to Evofem
Here is the latest report on Evofem's sector:
View
News related to Evofem
Media has covered Evofem for a total of 16 events in the last 1 year, 4 of them have been about company updates and 1 about partnerships.
鈥�
鈥�
鈥�
PR Newswire鈥�Feb 13, 2025鈥�Evofem
鈥�
PR Newswire鈥�Nov 15, 2024鈥�Evofem
鈥�
鈥�
鈥�
鈥�
鈥�
鈥�
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Evofem
Explore our recently published companies
- InnerScope Hearing Technologies - Roseville based, 2012 founded, Late Stage company
- Wittify.ai - Riyadh based, 2024 founded, Unfunded company
- Radiant Digitek - Kota based, 2014 founded, Unfunded company
- GoldPE - Chennai based, 2023 founded, Unfunded company
- Mumbai House Hotels - Mumbai based, 2017 founded, Unfunded company
- Green Energy Group - Flensburg based, 2023 founded, Unfunded company
